Quick answers
- What is TOUJEO Max?
- TOUJEO Max is a brand name of Insulin glargine, a prescription medicine. The FDA NDC Directory lists 2 TOUJEO Max products in 1 strength and form.
- Who makes TOUJEO Max?
- Sanofi US Services holds the FDA application for TOUJEO Max (BLA206538, approved February 25, 2015). 1 other company (repackagers or distributors) also list TOUJEO Max products.
- Is there a generic or store brand of TOUJEO Max?
- Yes. The FDA NDC Directory lists 4 other products with the same active ingredients, strength and form as a TOUJEO Max product. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for TOUJEO Max?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 1 TOUJEO Max strength and form (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has TOUJEO Max been recalled?
- No recall linked to TOUJEO Max products (by their NDC code or label) appears in the FDA enforcement reports we use.
What TOUJEO Max is
Each TOUJEO Max product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Insulin glargine · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| insulin glargine 300 units/mL injection, solution (subcutaneous) | TOUJEO Max | 4 products, 2 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Insulin glargine →
FDA approval
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| BLA206538 | Sanofi US Services | February 25, 2015 | 2 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| insulin glargine 300 units/mL injection, solution | Brand: TOUJEO Max | $91.28 per mL Generic of the same strength and form: $26.96–$26.99 per mL |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list TOUJEO Max
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of TOUJEO Max products.
- A-S Medication Solutions1 product
- Sanofi-Aventis U.S. LLC1 product
Recalls
No recall linked to TOUJEO Max products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.